CN1513468A - Compound medicine of sodium citicoline and disodium cytidine triphosphate - Google Patents
Compound medicine of sodium citicoline and disodium cytidine triphosphate Download PDFInfo
- Publication number
- CN1513468A CN1513468A CNA031527981A CN03152798A CN1513468A CN 1513468 A CN1513468 A CN 1513468A CN A031527981 A CNA031527981 A CN A031527981A CN 03152798 A CN03152798 A CN 03152798A CN 1513468 A CN1513468 A CN 1513468A
- Authority
- CN
- China
- Prior art keywords
- sodium
- cytidine triphosphate
- triphosphate
- composite reagent
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A medicine in the form of injection, perfusion, capsule, tablet, particles, etc for treating cerebrovascular disease and nerve injury is prepared from citicoline sodium, cytidine disodium triphosphate and medicinal additive. Its advantage is high curative effect.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of medicine for the treatment of cerebrovascular and nerve injury aspect disease.
Background technology
C14H25N4NaO11P2 is the sodium salt of nucleoside derivates citicoline, chemical name is a Cytidine Diphosphate Choline sodium, it is a necessary coenzyme during lecithin synthesizes, can strengthen reticular formation of brain stem especially with consciousness closely-related reticular formation of brain stem function, impel the damaged cell functional rehabilitation, can also strengthen cerebral blood flow in addition, improve the brain metabolism, be mainly used in function and disturbance of consciousness that central nervous system injury causes clinically.
Sodium Cytidine Triphosphate is the sodium salt of nucleoside derivates cytidine, chemical name is the cytidine triphosphate disodium, it not only can participate in the synthetic of phospholipid and nucleic acid directly, but also participate in energy metabolism in phospholipid and the nucleic acid building-up process indirectly, have the effect of trophic nerve, the anti-damage ability of raising neurocyte, the neurocyte activity that strengthens, promotion neurite-outgrowth and alleviation cerebrovascular sclerosis, be mainly used in cerebrovascular accident and sequela thereof, alzheimer disease, neurosis and cerebrovascular sclerosis etc. clinically.
The treatment mechanism of cerebrovascular and nerve injury disease is very complicated, and C14H25N4NaO11P2 and Sodium Cytidine Triphosphate treatment cerebrovascular and nerve injury respectively have its characteristics and advantage, and they have the excellent drug coordinating effect aspect treatment.
Summary of the invention
The purpose of this invention is to provide a kind of composite reagent thing (compound preparation) for the treatment of cerebrovascular and nerve injury aspect, this medicine have efficiently a therapeutic effect rapidly, the synergism of its folk prescription medicine is good, improve curative effect, more help the comprehensive therapy and the rehabilitation fast of cerebrovascular and nerve injury disease.
In order to achieve the above object, the present invention adopts C14H25N4NaO11P2 and Sodium Cytidine Triphosphate combination, make compound medicine, wherein the quality ratio range of C14H25N4NaO11P2 and Sodium Cytidine Triphosphate is 1: 0.01～2, and the Sodium Cytidine Triphosphate of the C14H25N4NaO11P2 of promptly per 1 mass parts and 0.01 to 2 mass parts is combined into combination drug.
It will be appreciated by those skilled in the art that, sign the multiformity in pharmaceutical dosage form, the dosage form of the compound preparation of C14H25N4NaO11P2 and Sodium Cytidine Triphosphate comprises dosage forms such as injectable powder, aqueous injection, sodium chloride transfusion, glucose infusion liquid, capsule, tablet, granule, oral liquid.
In addition, because the various dosage forms of preparation need be used the corresponding medicinal adjuvant, therefore when the medicine of the concrete dosage form of preparation, need select suitable pharmaceutic adjuvant for use, the kind of pharmaceutic adjuvant and consumption are selected for use according to the dosage form of medicine, and the pharmaceutic adjuvant of selecting for use should be convenient to medication preparation, stores, uses and promote Main Ingredients and Appearance C14H25N4NaO11P2 and Sodium Cytidine Triphosphate to absorb.
The specific embodiment
Embodiment one: C14H25N4NaO11P2 and lyophilized cytidine disodium triphosphate powder needle agent
Get C14H25N4NaO11P2 100 grams, Sodium Cytidine Triphosphate 20 grams, add the suitable quantity of water dissolving, regulate pH value between 6.0～8.0 with phosphate buffered solution, filter sterilization again, be distributed into 1000 bottles, the lyophilization rear seal-cover promptly makes the compound lyophilized powder of 20 milligrams of 100 milligrams of every bottle of phosphorous choline sodium and Sodium Cytidine Triphosphate, and wherein the quality proportioning of C14H25N4NaO11P2 and Sodium Cytidine Triphosphate is 1: 0.2.
Embodiment two: C14H25N4NaO11P2 and Sodium Cytidine Triphosphate aqueous injection
Get C14H25N4NaO11P2 180 grams, Sodium Cytidine Triphosphate 20 grams, add the suitable quantity of water dissolving, regulate pH value between 6.0～8.0, filter sterilization again, be distributed into 1000 bottles, make every bottle to be 4ml, sealing. promptly make every bottle of aqueous injection that contains 20 milligrams of 180 milligrams of C14H25N4NaO11P2s and Sodium Cytidine Triphosphate, wherein the quality proportioning of C14H25N4NaO11P2 and Sodium Cytidine Triphosphate is 1: 0.11.
Embodiment three: C14H25N4NaO11P2 and Sodium Cytidine Triphosphate sodium chloride intravenous infusion
Get C14H25N4NaO11P2 200 grams, Sodium Cytidine Triphosphate 10 grams, sodium chloride 900 grams add the suitable quantity of water dissolving, regulate pH value between 6.0～8.0, filter sterilization again, be distributed into 1000 bottles, make every bottle to be 200ml, sealing. promptly make every bottle of sodium chloride intravenous infusion that contains 10 milligrams of 200 milligrams of C14H25N4NaO11P2s and Sodium Cytidine Triphosphate, wherein the quality proportioning of C14H25N4NaO11P2 and Sodium Cytidine Triphosphate is 1: 0.05.
Should be noted that embodiment the, two, the 3rd, injection can add pharmaceutic adjuvants such as an amount of solubilizing agent, cosolvent, stabilizing agent, antioxidant as required in its prescription.
Embodiment four: C14H25N4NaO11P2 and Sodium Cytidine Triphosphate capsule
Get C14H25N4NaO11P2 90 grams, Sodium Cytidine Triphosphate 10 grams, starch 40 grams, lactose 45 grams, hydroxypropyl methylcellulose 3 grams, magnesium stearate 1 gram, add suitable quantity of water and stir and make soft material, soft material is crossed 20 eye mesh screen system granules, be packed into 1000 Capsules shell intermediate package after the drying and get final product, 10 milligrams of 90 milligrams of phosphorous choline sodium of its every capsules and Sodium Cytidine Triphosphate, wherein the quality proportioning of C14H25N4NaO11P2 and Sodium Cytidine Triphosphate is 1: 0.11.
Claims (4)
1. the composite reagent thing that comprises C14H25N4NaO11P2 and Sodium Cytidine Triphosphate.
2. composite reagent thing according to claim 1, the quality that it is characterized in that C14H25N4NaO11P2 and Sodium Cytidine Triphosphate join be 1: 0.01～2.
3. according to claim 1,2 described composite reagent things, it is characterized in that pharmaceutical dosage form comprises injectable powder, aqueous injection, sodium chloride transfusion, glucose infusion liquid, capsule, tablet, granule, oral liquid.
4. according to claim 1,2,3 described composite reagent things, it is characterized in that preparing various dosage forms and select the corresponding medicinal adjuvant for use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031527981A CN1513468A (en) | 2003-08-20 | 2003-08-20 | Compound medicine of sodium citicoline and disodium cytidine triphosphate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031527981A CN1513468A (en) | 2003-08-20 | 2003-08-20 | Compound medicine of sodium citicoline and disodium cytidine triphosphate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1513468A true CN1513468A (en) | 2004-07-21 |
Family
ID=34240677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031527981A Pending CN1513468A (en) | 2003-08-20 | 2003-08-20 | Compound medicine of sodium citicoline and disodium cytidine triphosphate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1513468A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109529016A (en) * | 2018-12-25 | 2019-03-29 | 江西润泽药业有限公司 | A kind of Citicoline sodium injection and preparation method thereof |
| CN111840220A (en) * | 2020-08-19 | 2020-10-30 | 开封康诺药业有限公司 | Citicoline sodium injection and preparation method thereof |
-
2003
- 2003-08-20 CN CNA031527981A patent/CN1513468A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109529016A (en) * | 2018-12-25 | 2019-03-29 | 江西润泽药业有限公司 | A kind of Citicoline sodium injection and preparation method thereof |
| CN109529016B (en) * | 2018-12-25 | 2022-07-15 | 江西润泽药业有限公司 | Citicoline sodium injection and preparation method thereof |
| CN111840220A (en) * | 2020-08-19 | 2020-10-30 | 开封康诺药业有限公司 | Citicoline sodium injection and preparation method thereof |
| CN111840220B (en) * | 2020-08-19 | 2022-09-30 | 开封康诺药业有限公司 | Citicoline sodium injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102670497A (en) | Stable S-oxiracetam preparation for injection and preparation method of same | |
| CN103781489B (en) | For the oral delivery of the carrier of oxygen based on hemoglobin | |
| CN101766597A (en) | Injection preparation with levo-oxiracetam as active component | |
| CN100418548C (en) | Medicinal composition and use thereof | |
| TW200812594A (en) | Medicine for prevention of and/or recovery from fatigue | |
| CN102302502A (en) | Compound glycyrrhizin preparation and preparation method thereof | |
| CN103110640B (en) | Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection | |
| CN1513468A (en) | Compound medicine of sodium citicoline and disodium cytidine triphosphate | |
| CN101467967B (en) | Double-element solution type preparation for intravenous injection and intracerebral injection | |
| CN103169756B (en) | Pharmaceutical composition of water-soluble vitamins for injection, fat-soluble vitamin injection and fat emulsion injection | |
| CN101229167B (en) | Method of preparing sodium levofolinate and applications thereof on preparing tumour-curing medicines | |
| CN103083322B (en) | Medicinal composition containing injection cefmenoxime hydrochloride and compound amino acid injection | |
| CN101829135A (en) | Injection preparation with citicoline sodium and inosine as active ingredients, and application thereof | |
| CN103169755B (en) | Pharmaceutical composition of water-soluble vitamins for injection, fat-soluble vitamins for injection and fat emulsion injection | |
| CN103768088B (en) | Pharmaceutical composition containing water-soluble vitamins for injection, fat-soluble vitamins for injection and medium/long-chain fat emulsion injection | |
| CN101926807A (en) | Fructose combination medicament | |
| CN102258507A (en) | Ibuprofen-containing pharmaceutical composition and its preparation method and application | |
| CN103239444A (en) | Dextroindobufen and clopidogrel compound drug composition | |
| CN104688670A (en) | Invokana sustained release preparation and preparation method thereof | |
| CN1562345A (en) | Drug combination including activator for metabolism of brain and free radical scavenger | |
| CN103768132B (en) | Pharmaceutical composition containing water-soluble vitamins for injection, fat-soluble vitamin injection and medium/long-chain fat emulsion injection | |
| CN101507723B (en) | Combination medicine capable of treating pneumonia and upper respiratory tract infection and preparation method thereof | |
| CN106074398A (en) | A kind of freeze dried lentinan holoside powder injecta and preparation method thereof | |
| CN107898805A (en) | A kind of 12 kinds of vitamin freeze-dried preparations of injection and preparation method thereof | |
| CN102716465B (en) | Pharmaceutical composite for treating tumor and preparation method of pharmaceutical composite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |